珍宝岛(603567.SH)：全资子公司获得药品注册证书

Core Viewpoint - The company has received approval for the production and sale of Moxifloxacin Hydrochloride Tablets, enhancing its product portfolio in the anti-infection sector [1][2]. Group 1: Product Approval - The company's wholly-owned subsidiary, Harbin Zhenbao Pharmaceutical Co., Ltd., has obtained the drug registration certificate for Moxifloxacin Hydrochloride Tablets from the National Medical Products Administration [1]. - Moxifloxacin is a broad-spectrum antibacterial agent effective against various bacteria, including Gram-positive, Gram-negative, anaerobic, and atypical microorganisms [1]. Group 2: Market Impact - The approval allows the company to expand its core product offerings in the anti-infection field, thereby increasing its competitiveness in the systemic anti-infection market [2]. - The introduction of Moxifloxacin Hydrochloride Tablets will not have a significant impact on the company's current operating performance [2].